297 related articles for article (PubMed ID: 12629351)
1. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer.
Chen Z; Fan Z; McNeal JE; Nolley R; Caldwell MC; Mahadevappa M; Zhang Z; Warrington JA; Stamey TA
J Urol; 2003 Apr; 169(4):1316-9. PubMed ID: 12629351
[TBL] [Abstract][Full Text] [Related]
2. Maspin is up-regulated in premalignant prostate epithelia.
Pierson CR; McGowen R; Grignon D; Sakr W; Dey J; Sheng S
Prostate; 2002 Dec; 53(4):255-62. PubMed ID: 12430137
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia.
Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z
J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling reveals hepsin overexpression in prostate cancer.
Magee JA; Araki T; Patil S; Ehrig T; True L; Humphrey PA; Catalona WJ; Watson MA; Milbrandt J
Cancer Res; 2001 Aug; 61(15):5692-6. PubMed ID: 11479199
[TBL] [Abstract][Full Text] [Related]
5. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer.
Stephan C; Yousef GM; Scorilas A; Jung K; Jung M; Kristiansen G; Hauptmann S; Kishi T; Nakamura T; Loening SA; Diamandis EP
J Urol; 2004 Jan; 171(1):187-91. PubMed ID: 14665873
[TBL] [Abstract][Full Text] [Related]
6. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
[TBL] [Abstract][Full Text] [Related]
7. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
8. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.
Luo J; Duggan DJ; Chen Y; Sauvageot J; Ewing CM; Bittner ML; Trent JM; Isaacs WB
Cancer Res; 2001 Jun; 61(12):4683-8. PubMed ID: 11406537
[TBL] [Abstract][Full Text] [Related]
9. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma.
Lucas JM; True L; Hawley S; Matsumura M; Morrissey C; Vessella R; Nelson PS
J Pathol; 2008 Jun; 215(2):118-25. PubMed ID: 18338334
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer.
Hirai K; Koizumi K; Haraguchi S; Hirata T; Mikami I; Fukushima M; Yamagishi S; Kawashima T; Okada D; Shimizu K; Kawamoto M
Ann Thorac Surg; 2005 Jan; 79(1):248-53. PubMed ID: 15620951
[TBL] [Abstract][Full Text] [Related]
11. Hepsin immunohistochemical expression in prostate cancer in relation to Gleason's grade and serum prostate specific antigen.
Goel MM; Agrawal D; Natu SM; Goel A
Indian J Pathol Microbiol; 2011; 54(3):476-81. PubMed ID: 21934206
[TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract][Full Text] [Related]
13. Expression of the tumor suppressor gene Maspin in human pancreatic cancers.
Maass N; Hojo T; Ueding M; Lüttges J; Klöppel G; Jonat W; Nagasaki K
Clin Cancer Res; 2001 Apr; 7(4):812-7. PubMed ID: 11309327
[TBL] [Abstract][Full Text] [Related]
14. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells.
Abraham S; Zhang W; Greenberg N; Zhang M
J Urol; 2003 Mar; 169(3):1157-61. PubMed ID: 12576872
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray analysis of maspin expression and its reverse correlation with mutant p53 in various tumors.
Zhang W; Zhang M
Int J Oncol; 2002 Jun; 20(6):1145-50. PubMed ID: 12011991
[TBL] [Abstract][Full Text] [Related]
16. Down-regulated expression of prostasin in high-grade or hormone-refractory human prostate cancers.
Takahashi S; Suzuki S; Inaguma S; Ikeda Y; Cho YM; Hayashi N; Inoue T; Sugimura Y; Nishiyama N; Fujita T; Chao J; Ushijima T; Shirai T
Prostate; 2003 Feb; 54(3):187-93. PubMed ID: 12518323
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
18. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
19. Maspin reduces prostate cancer metastasis to bone.
Hall DC; Johnson-Pais TL; Grubbs B; Bernal R; Leach RJ; Padalecki SS
Urol Oncol; 2008; 26(6):652-8. PubMed ID: 18367129
[TBL] [Abstract][Full Text] [Related]
20. Delineation of prognostic biomarkers in prostate cancer.
Dhanasekaran SM; Barrette TR; Ghosh D; Shah R; Varambally S; Kurachi K; Pienta KJ; Rubin MA; Chinnaiyan AM
Nature; 2001 Aug; 412(6849):822-6. PubMed ID: 11518967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
